Your session is about to expire
← Back to Search
GW433908 vs Nelfinavir for HIV
Study Summary
This trial will compare the effectiveness of two HIV drugs, GW433908 and nelfinavir, when each is given with abacavir and lamivudine to patients who have not previously taken antiretroviral drugs.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Find a Location
Who is running the clinical trial?
Media Library
- I am at least 13 years old and have consent if under 18.I have taken NRTI drugs for less than 4 weeks and never taken NNRT or PI drugs.I have a serious health condition like diabetes or heart disease.I haven't had chemotherapy or radiation in the last 28 days and won't need them during the study.I haven't taken immune-affecting or anti-HIV drugs in the last 28 days.I haven't taken certain drugs in the last 28 days and don't expect to need them during the study.I might qualify for this study.I cannot take medicines by mouth.I have had pancreatitis or hepatitis in the past 6 months.You have already tried new or experimental treatments.I have not had an HIV vaccine in the last 3 months.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Does this research allow for senior citizens to participate?
"According to the age requirements specified in this trial's inclusion criteria, the minimum age for participation is 13 and the maximum age is 0."
Are there any current openings for individuals in this research project?
"Unfortunately, this particular clinical trial is no longer recruiting patients, as noted on clinicaltrials.gov. This study was first posted on November 1st, 2000 but was last edited on June 23rd, 2005. Although this study is not taking any more participants, there are 495 other trials that are currently looking for patients."
Has this medication been federally approved in the United States?
"There is some evidence of this treatment's efficacy and it has undergone multiple rounds of testing, so Power rates its safety as a 3."
Are there any specific requirements for this trial's participants?
"The purpose of this study is to enroll 210 HIV positive individuals that are 13 years or older. In order to be eligible, potential participants must agree to use an effective method of birth control (such as spermicide in conjunction with a condom) during the study period, if they are of childbearing age. Additionally, applicants that have received nucleoside reverse transcriptase inhibitor treatment for less than 4 weeks, and have never received nonnucleoside reverse transcriptase inhibitor or protease inhibitor treatment in the past, are welcome to apply."
Share this study with friends
Copy Link
Messenger